First part of Belopenem formulation work is completed
Double Bond Pharmaceutical has now completed the first part of formulation work for Belopenem project. This means that the first formulation that successfully combines the active substance meropenem and the Belogal platform is now ready and satisfies the analytical specifications for Belogal as a targeted formulation. The next step will start shortly and will aim to verify the targeted effect of the formulation in vivo. “We are very satisfied with being able to keep the timeline and successfully complete the first step of the project, - Igor Lokot, CEO at Double Bond Pharmaceutical,